Merck Sharp & Dohme 8-K Merck Announces Fourth-Quarter and Full-Year 2008 Financial Results

Exhibit 99.2

MERCK & CO., INC.

OTHER FINANCIAL DISCLOSURES

FOURTH QUARTER

2008

EQUITY INCOME FROM AFFILIATES (millions of dollars)

	4Q `08		4Q `07		YTD 2008		YTD 2007
MERCK / SCHERING-PLOUGH	$	378.1	$	537.7	$	1,536.3	$	1,830.8
ASTRAZENECA LP		266.8		211.8		598.4		820.1
Other (1)		75.1		46.8		425.9		325.6
TOTAL	$	720.0	$	796.3	$	2,560.6	$	2,976.5

⁽¹⁾ Primarily reflects results for Merial Limited, Sanofi Pasteur-MSD and Johnson & JohnsonºMerck Consumer Pharmaceuticals.

JOINT VENTURE SALES DETAIL (millions of dollars)

All sales reported here are end-market JV sales, presented on a “NET” basis.

Merial	4Q `08		4Q `07		YTD 2008		YTD 2007
FRONTLINE, other fipronil	$	152.0	$	167.2	$	1,053.0	$	1,033.3
BIOLOGICALS		208.8		202.1		789.7		674.9
IVOMEC, HEARTGARD, other avermectins		96.8		111.7		511.8		478.4
Other Animal Health		67.4		70.2		288.2		262.2
TOTAL MERIAL SALES	$	525.0	$	551.2	$	2,642.7	$	2,448.8
Sanofi Pasteur-MSD	4Q `08		4Q `07		YTD 2008		YTD 2007
GARDASIL	$	171.2	$	231.0	$	865.3	$	476.0
VIRAL VACCINES		24.4		21.8		105.1		86.8
HEPATITIS VACCINES		15.9		19.0		72.6		72.9
Other Vaccines		265.1		267.3		841.8		802.3
TOTAL SANOFI PASTEUR-MSD SALES	$	476.6	$	539.1	$	1,884.8	$	1,438.0
Merck / Schering-Plough Collaboration	4Q `08		4Q `07		YTD 2008		YTD 2007
VYTORIN	$	549.5	$	775.9	$	2,360.0	$	2,779.1
ZETIA		524.7		678.6		2,201.1		2,407.1
TOTAL MERCK / SCHERING-PLOUGH SALES	$	1,074.2	$	1,454.5	$	4,561.1	$	5,186.2

OTHER (INCOME) EXPENSE, NET (millions of dollars)

	4Q `08			4Q `07			YTD 2008			YTD 2007
INTEREST INCOME	$	(147.2	)	$	(200.2	)	$	(631.4	)	$	(741.1	)
INTEREST EXPENSE		56.7			87.1			251.3			384.3
EXCHANGE LOSSES (GAINS)		73.8			(14.5	)		147.4			(54.3	)
MINORITY INTERESTS		30.0			29.4			123.9			121.4
Other, net(1)		(10.1	)		665.6			(2,085.4	)		335.9
TOTAL	$	3.2		$	567.4		$	(2,194.2	)	$	46.2

⁽¹⁾ Other, net for full year 2008 primarily reflects a gain of $2.2 billion related to a distribution from AstraZeneca LP. Other, net for the fourth quarter and full year 2007 reflects a civil governmental investigations charge of $671.1 million.

MERCK & CO., INC.

OTHER FINANCIAL DISCLOSURES

FOURTH QUARTER

2008

NET PRODUCT SALES DETAIL (millions of dollars)

	4Q `08 vs. 4Q `07
PRODUCT	TOTAL % CHG		TOTAL $	U.S. % CHG		U.S. $	Foreign % CHG		Foreign $
COZAAR / HYZAAR	-1	%	881	-3	%	319	—		562
FOSAMAX	-60	%	318	-85	%	77	-12	%	241
SINGULAIR	-3	%	1,122	-11	%	709	15	%	413
Vaccines:
GARDASIL	-16	%	286	-19	%	216	-2	%	69
ROTATEQ	9	%	162	4		148	*		14
ZOSTAVAX	89	%	162	89	%	162	N/A		—
OTHER VIRAL VACCINES(1)	-10	%	295	-11	%	278	3	%	17
HEPATITIS VACCINES(2)	-33	%	40	-32	%	33	-38	%	7
OTHER VACCINES(3)	5	%	132	8	%	97	-2	%	35
Other Reported Products:
ARCOXIA	-1	%	83	N/A		—	-1	%	83
CANCIDAS	4	%	139	4	%	21	4	%	118
COSOPT / TRUSOPT	-27	%	154	-62	%	37	1	%	117
CRIXIVAN / STOCRIN	-35	%	52	-34	%	3	-35	%	49
EMEND	16	%	71	23	%	47	6	%	24
INVANZ	29	%	68	35	%	38	21	%	30
ISENTRESS	*		130	*		71	*		59
JANUVIA	64	%	413	41	%	323	*		89
JANUMET	*		120	*		99	*		20
MAXALT	12	%	141	15	%	97	7	%	44
PRIMAXIN	-13	%	169	-24	%	39	-10	%	130
PROPECIA	-4	%	108	-5	%	37	-3	%	71
PROSCAR	-14	%	72	-46	%	2	-12	%	69
TIMOPTIC / TIMOPTIC XE	-3	%	31	-9	%	2	-3	%	29
VASOTEC / VASERETIC	-32	%	85	N/A		—	-32	%	85
ZOCOR	-34	%	147	-80	%	11	-19	%	136
ZOLINZA	64	%	5	62	%	4	*		—

* 100% or over

N/A - Not Applicable

⁽¹⁾        - Includes ProQuad, M-M-R II and Varivax.

⁽²⁾     - Includes Recombivax and Vaqta

⁽³⁾     - Includes Pneumovax, Comvax and Pedvaxhib

TOTAL SALES: VOLUME, PRICE, EXCHANGE

	4Q `08		% CHG		VOL	PX	FX
TOTAL PHARMACEUTICAL SALES	$	6,032	-3	%	-4	1	-1
U.S. ($ MM)		3,396	-9	%	-12	4	N/A
Foreign ($ MM)		2,636	5	%	10	-3	-2

MERCK & CO., INC.

OTHER FINANCIAL DISCLOSURES

DECEMBER YEAR-TO-DATE

2008

NET PRODUCT SALES DETAIL (millions of dollars)

	DECEMBER YTD `08 vs. DECEMBER YTD `07
PRODUCT	TOTAL % CHG		TOTAL $	U.S. % CHG		U.S. $	Foreign % CHG		Foreign $
COZAAR / HYZAAR	6	%	3,558	1	%	1,247	9	%	2,311
FOSAMAX	-49	%	1,553	-75	%	498	-1	%	1,054
SINGULAIR	2	%	4,337	-6	%	2,825	19	%	1,511
Vaccines:
GARDASIL	-5	%	1,403	-13	%	1,041	26	%	362
ROTATEQ	27	%	665	24	%	618	83	%	46
ZOSTAVAX	32	%	312	32	%	312	N/A		—
OTHER VIRAL VACCINES(1)	-6	%	1,268	-8	%	1,175	38	%	94
HEPATITIS VACCINES(2)	-47	%	148	-52	%	112	-21	%	36
OTHER VACCINES(3)	-13	%	355	-32	%	206	38	%	149
Other Reported Products:
ARCOXIA	15	%	377	N/A		—	15	%	377
CANCIDAS	11	%	596	-21	%	100	21	%	496
COSOPT / TRUSOPT	-1	%	781	-17	%	291	12	%	491
CRIXIVAN / STOCRIN	-11	%	275	-36	%	13	-10	%	262
EMEND	29	%	264	24	%	172	41	%	92
INVANZ	39	%	265	32	%	138	48	%	127
ISENTRESS	*		361	*		202	*		159
JANUVIA	*		1,397	79	%	1,110	*		287
JANUMET	*		351	*		308	*		43
MAXALT	13	%	529	13	%	354	14	%	175
PRIMAXIN	—		760	-22	%	163	8	%	598
PROPECIA	6	%	429	-1	%	151	10	%	278
PROSCAR	-21	%	324	-79	%	12	-12	%	311
TIMOPTIC / TIMOPTIC XE	2	%	122	-10	%	7	2	%	115
VASOTEC / VASERETIC	-28	%	357	N/A		—	-28	%	357
ZOCOR	-25	%	660	-59	%	75	-16	%	585
ZOLINZA	40	%	15	34	%	14	*		1

*    100% or over

N/A -  Not Applicable

⁽¹⁾ -  Includes ProQuad, M-M-R II and Varivax.

⁽²⁾ -  Includes Recombivax and Vaqta

⁽³⁾ -  Includes Pneumovax, Comvax and Pedvaxhib

TOTAL SALES: VOLUME, PRICE, EXCHANGE

	FY `08		% CHG		VOL	PX	FX
TOTAL PHARMACEUTICAL SALES	$	23,850	-1	%	-4	—	3
U.S. ($ MM)		13,370	-9	%	-11	2	N/A
Foreign ($ MM)		10,480	10	%	7	-4	7